Comparing immune response after two HPV vaccines in girls
Part of Infections clinical trials.
This study compares the immune response (antibodies) in girls aged 13-14 who have completed either a domestic or imported HPV vaccine. It aims to see if the two vaccines produce similar protection, which might help confirm the effectiveness of the domestic option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have received all doses of either the domestic bivalent HPV vaccine or the imported HPV vaccine.
- Your last dose should have been 30 to 60 days before you start the study.
- You must be 13 or 14 years old at the time of your first vaccine dose.
- You and your guardian must be able to provide proof of identity and sign a consent form.
- You must be willing to come for follow-up visits and have blood drawn as needed.
- You cannot have received other HPV vaccines or participated in other vaccine studies recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares how well your immune system responds to an HPV vaccine given as either 2 doses or 3 doses in people ages 27–45 who have never had the HPV vaccine. It may help improve HPV prevention strategies and guide the best dose schedule for adults.
This study looks at how well the HPV vaccine works in women who have already been exposed to the virus through sexual activity. It aims to understand the immune response and potentially improve protection against HPV-related cancers.
This trial tests an 11-type HPV vaccine to prevent infection from multiple HPV strains. If you enroll, you’ll receive scheduled vaccine doses and have health and gynecologic check-ins to see how well the vaccine works and is tolerated.
This study looks at the safety and immune response of a 9-valent HPV vaccine. It is for women who have already received a full course of certain HPV vaccines and are now getting a different one to see if it boosts their immunity.
This Phase 1 study tests FluBHPVE6E7, a new treatment designed to help the immune system respond to HPV16. It mainly checks safety and the best dose, and may help your body clear or control HPV over time.
This study checks if one dose of the 9-valent HPV vaccine given at ages 9-11 still protects you 6 years later. It is for people who only had that single dose and no other HPV shots.
Hear when a new HPV Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.